Forbes: “Clinical Trial For Brain Cancer Treatment Has Promising Results”

Brain Tumor Investment Fund (BTIF) portfolio company, Alpheus Medical, was recently featured in an article on the magazine Forbes’s website. The article highlights encouraging results from an ongoing clinical trial evaluating Alpheus’s LIDU® system in patients with glioblastoma. This novel therapeutic approach – known as sonodynamic therapy – uses low-intensity ultrasound to activate a tumor-targeting drug inside the brain, with the goal of selectively destroying cancer cells while minimizing damage to healthy tissue.

The therapy is designed to overcome one of the major challenges in brain tumor treatment — delivering therapy throughout the brain while limiting systemic toxicity — and could represent an important new approach if clinical trials continue to show positive results. Currently, the company is enrolling patients with newly diagnosed glioblastoma in a phase 2b clinical trial at eight sites in the United States.

This national media coverage reflects the growing momentum behind innovative treatment strategies in neuro-oncology and underscores the importance of continued investment in companies working to develop new therapies for patients with brain tumors. Read the full article in Forbes, here.

---

Disclaimer: BTIF is not responsible for content on 3rd party sites.

---